Ubrogepant

UBRELVY is indicated for the acute treatment of migraine with or without aura in adults.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: UBRELVY is indicated for the acute treatment of migraine with or without aura in adults.
Do not take if: With concomitant use of strong CYP3A4 inhibitors
In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. Reactions have included anaphylaxis, dyspnea, and facial or throat edema

What it is used for

Limitations of Use

UBRELVY is not indicated for the preventive treatment of migraine.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in labeling:

Hypersensitivity Reactions
Hypertension
Raynaud’s Phenomenon

Who should not take it

UBRELVY is contraindicated:

With concomitant use of strong CYP3A4 inhibitors
In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. Reactions have included anaphylaxis, dyspnea, and facial or throat edema

Storing it

Store between 20°C and 25°C (68°F and 77°F): excursions permitted between 15°C and 30°C (59°F and 86°F) [ see USP Controlled Room Temperature ].

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Ubrogepant; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/ubrogepant
APA 7th: sofidex. (2026, August 3). Ubrogepant. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/ubrogepant
AMA 11th: Ubrogepant. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/ubrogepant

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.